FDA Approves New Heart Valve Leak Device

This minimally invasive tool helps patients treat leaks after valve replacement surgery without repeat open-heart procedures.

Updated on Oct. 28, 2026 in Heart Disease

Bold vector editorial illustration of a stylized medical occlusion device and tissue cross-section, illustrating a minimally invasive heart procedure. — The FDA approved the Amplatzer Paraclose PVL Occluder, a transcatheter device offering a minimally invasive treatment for paravalvular leaks following valve replacement surgery. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical devices effectively reduce the need for repeat open-heart surgeries?

The FDA has approved the Amplatzer Paraclose PVL Occluder, a new device designed to treat paravalvular leaks following heart valve replacement. This minimally invasive option provides a new alternative for patients who might otherwise require repeat open-heart surgery.

Why it matters

Paravalvular leaks, which cause symptoms like shortness of breath and fatigue, occur in up to 17% of patients after valve replacement. This approval offers a less invasive path to resolve these complications and improve patient quality of life.

The approval is supported by the PARADIGM study, which evaluated the device in 200 patients. Paravalvular leaks currently affect 7% to 17% of mitral and 5% to 10% of aortic valve replacements, though long-term efficacy relative to standard care remains under study.

The players

FDA

The United States federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.

The details

The Amplatzer Paraclose PVL Occluder is a transcatheter device implanted via a catheter through a vein or artery in the leg. Its elliptical shape is engineered to seal various leak anatomies, preventing blood from flowing around the valve's outer edge. By physically closing these gaps, the device addresses conditions like hemolysis and heart failure symptoms that can arise when a replacement valve does not seal perfectly against the heart tissue.

October 28, 2026: The FDA officially approved the Amplatzer Paraclose PVL Occluder for use.

Health Landscape

This device represents a technical evolution in the repair of complications following the historical shift toward transcatheter heart valve replacement. It aims to reduce the reliance on repeat open-heart surgeries, which have long been the standard approach for managing prosthetic valve leaks.

If you have experienced symptoms like shortness of breath or persistent fatigue following a heart valve replacement, it is worth discussing this treatment option with your cardiologist. They can determine if this minimally invasive approach is appropriate based on your specific valve anatomy and medical history.

The takeaway

The new Amplatzer Paraclose PVL Occluder provides a less invasive method for managing dangerous leaks after valve replacement surgery. Patients with existing valve implants should monitor for symptoms like leg swelling or fatigue and consult their physician about current options for managing valve function.